Dextromethorphan-Bupropion Combination for Sustained Plasma Levels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments with dextromethorphan often result in rapid metabolism, leading to low plasma levels and adverse events, particularly in extensive metabolizers, and require frequent dosing due to short half-life.
Innovation Solution
Co-administration of bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion with dextromethorphan to inhibit metabolism and increase plasma levels, thereby reducing adverse events and extending the duration of therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dextromethorphan is administered to extensive metabolizers, then therapeutic effect is achieved, but plasma levels are low and adverse events occur due to rapid metabolism
Solution Approach 1:
The patent introduces bupropion as an intermediary substance that inhibits the metabolism of dextromethorphan. Bupropion acts as a mediator between dextromethorphan and the metabolic process, blocking the enzyme that rapidly metabolizes dextromethorphan in extensive metabolizers, thereby increasing plasma levels and reducing adverse events while maintaining therapeutic effect.
Solution Approach 2:
The patent changes the metabolic parameter of dextromethorphan by co-administering bupropion, which alters the metabolism rate from rapid (extensive) to slowed-down. This parameter change increases the half-life and plasma concentration of dextromethorphan, transforming the pharmacokinetic profile to achieve therapeutic levels without excessive metabolism.
2Reliability
If dextromethorphan is administered frequently to maintain plasma levels, then therapeutic effect is maintained, but dosing complexity and patient burden increase
Solution Approach 1:
The patent applies preliminary action by co-administering bupropion before and with dextromethorphan doses. This preliminary preparation inhibits the metabolic pathway in advance, allowing for reduced dosing frequency while maintaining therapeutic plasma levels. The preliminary inhibition of metabolism enables less frequent dosing without compromising therapeutic effect.
Solution Approach 2:
The patent ensures continuity of useful action by maintaining metabolic inhibition through continuous presence of bupropion. This continuous inhibition of the metabolic enzyme extends the half-life of dextromethorphan, allowing therapeutic levels to be maintained over longer periods without frequent dosing, thus simplifying the dosing regimen while maintaining therapeutic reliability.
3Reliability
If dextromethorphan plasma levels are increased to reduce adverse events, then therapeutic outcomes improve, but metabolism inhibition must be achieved
Solution Approach 1:
The patent uses bupropion as a simple intermediary mechanism to achieve metabolism inhibition. Rather than directly targeting the metabolic enzyme complex, bupropion serves as a straightforward inhibitor that blocks the cytochrome P450 enzyme responsible for dextromethorphan metabolism, providing a simple and effective way to increase plasma levels and improve therapeutic outcomes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances dextromethorphan plasma levels, decreases dextrorphan plasma levels over time, and reduces adverse events by inhibiting metabolism, allowing for less frequent dosing and improved therapeutic outcomes.
Implementation Method 1
Co-administration of bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion with dextromethorphan to inhibit metabolism and increase plasma levels
Data Source
AI summary
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.